Cigna said on Wednesday it was launching an add-on to pharmacy benefit management plans in which patients could pay no more ...

Cigna Group’s drug benefit unit is offering a new way for health plans to cover expensive weight-loss drugs that it says will ...

As the popularity of weight-loss drugs surges, a new concern is emerging: “Ozempic teeth.” The term refers to a range of dental issues users have reported experiencing, such as dry mouth, bad breath, ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

After adjusting for the weight loss benefits of surgery, GLP-1 drugs were linked to a 41% lower risk of obesity-related ...

The Attorney General of Connecticut is describing a series of weight-loss drugs being sold online as untested and unsafe. The ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

A new head-to-head study reveals tirzepatide achieves 47% more weight loss than semaglutide in people with obesity but without diabetes, highlighting its superior effectiveness and cardiometabolic ...

Cigna subsidiary Evernorth Health Services will authorize prior authorizations for GLP-1 weight-loss drugs under a new ...

Injectable drugs like Ozempic and Mounjaro have transformed obesity treatment by mimicking gut hormones. But experts have ...

The companies are allegedly selling "research grade" GLP-1 weight loss drugs that are not FDA-approved, and are selling the products without a pharmacy license.

SaveHealth explores the historical trajectory of weight loss drugs, examining their scientific basis, regulatory battles, public reception, and what lies ahead for pharmacotherapy in obesity ...